Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -35.00p -17.28% 167.50p 160.00p 175.00p 202.50p 167.50p 202.50p 23,302.00 15:53:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.4 -6.5 -122.8 - 9.10

Akers Biosciences (AKR) Latest News

More Akers Biosciences News
Akers Biosciences Takeover Rumours

Akers Biosciences (AKR) Share Charts

1 Year Akers Biosciences Chart

1 Year Akers Biosciences Chart

1 Month Akers Biosciences Chart

1 Month Akers Biosciences Chart

Intraday Akers Biosciences Chart

Intraday Akers Biosciences Chart

Akers Biosciences (AKR) Discussions and Chat

Akers Biosciences Forums and Chat

Date Time Title Posts
04/12/201615:02Akers Biosciences Inc 20113,329.00
24/8/201507:47Akers biosciences229.00
05/9/201412:48Reasons to BUY in Akers Bioscience (AKR)-
01/9/201319:40FDR Aprrobval due to today4.00
14/1/201100:33Akers Biosciences Inc - 2010 Thread54.00

Add a New Thread

Akers Biosciences (AKR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Akers Biosciences trades in real-time

Akers Biosciences (AKR) Top Chat Posts

DateSubject
04/12/2016
08:20
Akers Biosciences Daily Update: Akers Biosciences, Inc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AKR. The last closing price for Akers Biosciences was 202.50p.
Akers Biosciences, Inc has a 4 week average price of 209.50p and a 12 week average price of 228.67p.
The 1 year high share price is 245p while the 1 year low share price is currently 82.50p.
There are currently 5,434,212 shares in issue and the average daily traded volume is 11,502 shares. The market capitalisation of Akers Biosciences, Inc is £9,102,305.10.
02/12/2016
12:40
ramridge: wigwammer - Here is an extract from yesterday's RNS " Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL") cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL") levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol. " Well, that is a blatant lie. It is not the only such product in the market. A few minutes of googling providing me with information about quite a few others in the market able to analyse to the same degree. Below is just one example: " Cholesterol Home Test: The one name that comes up most often for home cholesterol tests is CardioChek. They have the more scientific looking devices that sell for over $100 and promise clinically accurate results. Their blood analyzers do score better in tests than the less expensive paper strips without an electronic device to analyze them. The top rated CardioChek Home Blood Analyzer # 730, 1 ea is one that we found listed all over the Internet. Not all owner reviews are positive, but it did more praise than other systems. The device uses color coded PTS PANELS test strips that get inserted into the machine and you get a readout for Total Cholesterol, HDL Cholesterol, Triglycerides, Glucose and Ketone. The digital display will give you the details usually after 1 to 2 minutes of analysis. You get 2 test strips in the package along with 2 AAA batteries that it requires to run. " My point is this. As a result of management putting out this blatant lie (at best management is incompetent if they were not aware of such competing products, or at worse deliberately misleading the public), the share price spiked yesterday to as much as 255p before crashing. Go tell the guys who bought on the news that this is not important but HIT, etc is . This is misleading the market in a serious way that should not go unpunished.
01/12/2016
19:38
mcmather: Aye, but this one also sounded promising. 8 years ago... "Akers Biosciences, Inc, a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has signed an agreement with a large U.S. distributor specialising in over-the-counter diagnostic products. The distributor, who cannot be named for commercial reasons, will market several of the Company's products to the U.S. retail market, including Tri-Cholesterol, the only disposable, rapid test in the world to read HDL, LDL and Total cholesterol levels. Marketing of ABI's products under the agreement will begin immediately to drug, food and convenience stores and mass retailers. Clients include such retailers as Kmart, Wal-Mart, CVS, Walgreens, 7-Eleven, Safeway, Costco and Target". http://uk.advfn.com/stock-market/london/akers-biosciences-AKR/share-news/U-S-Over-the-Counter-Distribution-Agreement/29417227
15/11/2016
12:12
rivaldo: No callers eh - that's what you call "under the radar" :o)) They definitively say that Q4 "is expected to be profitable", and that the rest of the $2.5m Chinese order will be received this quarter. So these things had better happen. I suspect when/if they announce the receipt of the Chinese cash the share price may go a fair bit higher. Here's a link to the conference call for the record: Http://seekingalpha.com/article/4023217-akers-biosciences-aker-ceo-john-gormally-q3-2016-results-earnings-call-transcript?part=single
30/6/2016
06:19
rivaldo: Wow - AKR announce the "highly successful" completion of a trial for "the first rapid test for Chlamydia diagnosis using a finger stick blood sample": Http://www.investegate.co.uk/akers-biosciences--akr-/rns/clinical-trial-for-rapid-chlamydia-test-completed/201606300700097101C/ Imagine the potential for this test and the potential global take-up.... There's certainly nothing in the share price for this on a mere £9m m/cap.
29/2/2016
15:05
mcmather: btw share price on nasdaq of US$1.64 = £1.17 approx. A share price on nasdaq of US$1.72 = £1.23 approx.
18/8/2015
08:13
mcmather: 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
05/8/2015
21:44
mcmather: Depends whether you are including the below in the "us" bit? 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN Good luck wolfie and waylander by the way.
16/7/2015
22:34
mcmather: This from around 2008/09: Rep. Rob Andrews (NJ-1) requests $20,000,000 for: Akers Biosciences Inc. 201 Grove Road Thorofare, NJ 08086. hTtps://washingtonwatch.com/bills/show/ED_8072.html This from 30 June 2015: In addition, Mr. Andrews was appointed to the Company's Governance and Nominating Committee, Compensation Committee and Audit Committee; and will serve as the Chairman of the Company's Compensation Committee. Anyone guess where this is going?? This from the heading: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Discussion welcome on the thread. 23 July 2013 - Dr Raymond Akers disposes of 7m shares; roughly £140,000. 8 August 2013 - Proposed Nasdaq listing. 18 November 2013 - Share consolidation; 156/1. 23 January 2014 - Listing opens on Nasdaq. 14 May 2014 - Q1 2014 results - Net loss $595,600 mainly due to costs associated with NASDAQ IPO. 12 August 2014 - Q2 2014 results - Net loss $494,995 Three factors contributed to the increased loss: maintaining dual listings of our stock has significantly increased costs associated with compliance with regulatory requirements, the expansion of sales and marketing efforts and stock option based compensation for our directors, officers and key employees. 13 November 2014 - Q3 2014 results - Net loss $1,124,320 as a result of hiring additional personnel, capital market commitments and marketing activities. 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
09/3/2015
17:56
mcmather: Norbus, re Dr Raymond Akers Jnr's 'activities' here, I'd suspect that there are one or two - perhaps quite a few more? - paying close attention to all ongoing including this from an earlier post on here: $650,000 for a company which will later announce massive losses for 2014; his remuneration package will equate to around 14.5% of all (gross, not net) revenue generated by the company in 2014. As the heading asks: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) The Mail Online appears to have 100m unique hits / visitors per month and this fella tipped them as his share for 2015: Ian Lyall - Akers Bioscience If you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company. http://www.thisismoney.co.uk/money/investing/article-2890431/Shares-vote-2015-Daily-Mail-s-City-reporters-reveal-market-tips.html#ixzz3Tubf4INL
15/2/2015
23:49
mcmather: Save the best till last... 24.10 I think it (the company / the current stock price) is just an absolute steal of a buy at the moment. I am so confident of this that me, Thomo', Little Tommy and our Gav' invested $674,000 in buying 180,00 shares. Sorry, what's that Maureen? I can't say that because we did NOT part with any money - least of all our own - but simply awarded them to ourselves? Crikey, thanks Maureen, I think we might just have got away with that.... 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
Akers Biosciences share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161204 16:18:39